Rationale and methods of the Antioxidant and NMDA receptor blocker Weans Anoxic brain damage of KorEa OHCA patients (AWAKE) trial.

Jin Ho ChoiByeong Jo ChunSeok Ran YeomSung Phil ChungYoung Hwan LeeYun-Hee KimJi Sung LeeJin Hwan LeeHwan Goo LeeJing Yu JinChun San AnByoung Joo Gwag

Published in: Trials (2022)

ClinicalTrials.gov NCT03651557 . Registered on August 29, 2018.

Keyphrases

end stage renal disease
oxidative stress
ejection fraction
clinical trial
newly diagnosed
chronic kidney disease
prognostic factors
study protocol
randomized controlled trial
white matter
subarachnoid hemorrhage
patient reported
cerebral ischemia